• 대한핵의학회지
• /
• 제33권1호
• /
• pp.11-27
• /
• 1999

Peptide imaging is a new diagnostic modality in nuclear medicine. $^{111}In$-pentetreotide ($Octreoscan^R$) is the first commercially available peptide radiopharmaceutical. This review article presents the results of previous studies using $^{111}In$-pentetreotide for several disease states, including neuroendocrine tumors, breast cancer and malignant lymphoma. The use of hand-held probe during surgery and the preliminary results of radiotherapy using radiolabeled somatostatin analogues are also reviewed. It can be concluded that somatostatin receptor scintigraphy is a promising diagnostic tool for localizing primary tumors that express receptors for somatostatin, staging secondary spread of tumor tissue, following up after therapy and identifying patients who may benefit from therapy with unlabelled or radiolabeled octreotide. The somatostatin receptor imaging will stimulate the development of new radiopharmaceuticals for other receptors and enhance the therapeutic use of radiolabeled peptides.

• 대한핵의학회지
• /
• 제28권3호
• /
• pp.377-383
• /
• 1994

완전 치유되었던 골임파종 환자에서 치료효과를 판정하기 위해 치료후 $^{99m}Tc$-MDP 스캔과 $^{67}Ga$ 스캔으로 추적검사한 35례를 후향적으로 분석하였다. $^{99m}Tc$-MDP 스캔은 35례중 29례에서 치료중, 33례에서 치료후 추적검사하였고, $^{67}Ga$ 스캔은 16 례중 13례에서 치료중, 15례에서 치료후 추적검사를 하였다. 핵의학적검사의 병적섭취농도의 분류는 4단계로 나누었는데 $^{99m}Tc$-MDP 스캔의 경우 정상 천장골관절 섭취농도와 같은 병변의 섭취농도를 3으로, $^{67}Ga$ 스캔의 경우 정상간의 섭취농도와 같은 병변의 섭취농도를 3으로 기준하였다. 치료중과 치료후 치료효과를 나타내는 소견은 $^{99m}Tc$-MDP 스캔의 경우 각각 66.0%(19/29), 72.7%(24/33)였으며 $^{67}Ga$ 스캔의 경우 각각 84.6%(l1/13), 86.7%(13/15)였다. 치료전, 치료중, 치료후의 병변 섭취농도는 $^{99m}Tc$-MDP 스캔의 경우 각각 3.06, 2.34, 1.75였으며, $^{67}Ga$ 스캔의 경우 각각 3.22, 1.42, 1.30이었다. 따라서 골임파종에서 치료효과를 판정하는 추적검사로는 $^{67}Ga$ 스캔이 $^{99m}Tc$-MDP 골 스캔보다 더 예민한 결과를 나타내었다.

• 대한방사성의약품학회지
• /
• 제3권2호
• /
• pp.80-84
• /
• 2017

Re-188 is an excellent and practical radioisotope produced by W-188/Re-188-generator for therapy. We prepared Re-188-tin colloid for therapy of various diseases and tried to treat peritoneal effusion in animal model. Sarcoma-180 cells were injected into ICR mice to induce peritoneal effusion and the mice were grown for 3 d. Re-188-tin colloids (0.25, 0.5, and 1 mCi/mL per 30 g body weight) were injected into the mice and the mice were grown for 90 d. Planar gamma scintigraphy showed even distribution of Re-188-tin colloid radioactivity. Bax expression was found to be dose dependent to Re-188-tin colloid. Normal saline treated group showed the shortest survival time. Among the treated groups, 0.5 mCi dose group showed the longest survival time. In conclusion, Re-188-tin colloid was prepared successfully and showed the feasibility to use as a peritoneal effusion treatment in mice.

• 대한방사성의약품학회지
• /
• 제5권1호
• /
• pp.26-35
• /
• 2019

$^{188}Re$ is one of the most readily available generator derived and useful radionuclides for therapy emitting ${\beta}^-$ particles (2.12 MeV, 71.1% and 1.965 MeV, 25.6%) and imageable gammas (155 keV, 15.1%). The $^{188}W/^{188}Re$ generator is an ideal source for the long term (4-6 months) continuous availability of no carrier added (NCA) $^{188}Re$ suitable for the preparation of radiopharmaceuticals for radionuclide therapy. Rhenium-188 has been used for the preparation of therapeutic radiopharmaceuticals for the management of diseases such as bone metastasis, rheumatoid arthritis and primary cancers. Several early phase clinical studies using radiopharmaceuticals based on $^{188}Re$ -labeled phosphonates, antibodies, peptides, lipiodol and particulates have been reported. In this review, we addressed the current development status of $^{188}Re$ radiopharmaceuticals for liver cancer therapy and their applications.

• Nuclear Engineering and Technology
• /
• 제55권10호
• /
• pp.3815-3821
• /
• 2023

Dosimetric studies in Nuclear Medicine are very important, especially with new therapeutic methods, the number of which has increased significantly with the Theranostic approach (determining diagnostic-therapeutic pairs where similar molecules are labelled with different isotopes in order to diagnose and treat malignant diseases). Peptide receptor radionuclide therapy (PRRT) has been used successfully for many years to treat neuroendocrine tumors (NET). ⁹⁰Y-DOTATOC is one of the radiopharmaceuticals used frequently in this type of therapy. In this work, blood and urine samples from 13 patients treated with ⁹⁰Y-DOTATOC were measured by a liquid scintillation beta counter (LSC). Calibration of the beta counter for this type of measurement was done and all results are presented in the paper. The presented paper also provides a methodology for determining the measurement uncertainty for this type of measurement. Immediately after the administration of radiopharmaceuticals, the activity in the blood was different from 6.31% to 88.9% of the applied radioactivity, while 3 h after the termination of the application, the average value of radiopharmaceuticals in the blood was only 3.84%. The activity in the excreted urine depended on the time when the patients urinated after the therapy. It was measured that as much as 58% of the applied radioactivity was excreted in the first urine after the therapy in a patient who urinated 4.5 h after the completed application of the therapy. In most patients, the highest urine activity was in the first 10 h after the application, while the activities after that time were negligibly low. The described methodology of measuring and evaluating activity in blood and excreted urine can be applied to other radiopharmaceuticals used in nuclear medicine. It could be useful for researchers for dosimetric assessments in clinical application of PRRT.

• 대한핵의학회지
• /
• 제24권1호
• /
• pp.24-28
• /
• 1990

Various urodynamic studies have been used in patients with bladder outlet obstruction in order to evaluate the degree of obstruction, the results of therapy and postprostatectomy conditions. Radionuclide urodynamic study was performed in 27 patients with bladder outlet obstruction and 30 normal controls. The parameters evaluated were voiding time, 50% voiding time, average flow rate, peak flow rate, corrected peak flow rate, ejection fraction of the bladder and residual urine. Voiding time, 50% voiding time and residual urine of patients were significantly larger than controls and average flow rate, Peak flow rate, peak corrected flow rate and ejection fraction were significantly lower in patients. This method was noninvasive procedure for determining of voiding parameters and it avoids the extraexamination needs to determine the residual urine.

• 대한핵의학회지
• /
• 제38권4호
• /
• pp.275-281
• /
• 2004

Compared with the earlier technique of dual photon absorptiometry (DPA) using $^{153}Gd$ radionuclide source, dual energy X-ray absorptiometry (DXA) has advantages of higher precision, accuracy and shorter scanning time. Despite the change from DPA to DPX, the nuclear medicine physicians has remained one of major suplier of this service due to long-standing use of DPA. Among many kinds of bone densitometries, DXA is the "gold standard" for the noninvasive diagnosis of osteoporosis. Especially there is no role for peripheral devices in the monitoring of patients on therapy. But, there are some areas of controversy related to the application of DXA, such as proper site of measurement, accurate interpritation, appropriate use of T-score, and the reference population young database. And the accuracy, precision, and quality control issues relating to bone density measurement are important subjects. To address these issues, the International Society for Clinical Densitometry (ISCD) has convened two Position Development Conferences and addressed official positions. This review deals the key elements of ISCD position paper and other important issues on the management of bone densitometry.

• 대한핵의학회지
• /
• 제31권4호
• /
• pp.427-432
• /
• 1997

Re-188은 반감기가 17시간이고 진단을 위한 영상화가 가능한 감마선(155keV)을 방출하며 치료용으로 적당한 베타선(2.12MeV)을 동시에 방출하여 혈관성형술 풍선에 넣어 조사하는 접촉 베타선 방출체 치료용 방사성핵종으로 유력하다. 이 연구에서는 Re-188-DTPA를 관상동맥풍선 성형술시 풍선에 주입하는 방사성 동위원소로 쓸 수 있을지 알기 위해 우선 표지법과 풍선에서 혈관내로 샜을 때의 생체내 분포를 조사하였다. Re-188과 DTPA를 표지하는 방법을 확립하였고 표지효율은 95%, 실온과 사람 혈청에서 안정하였다. 마우스의 체내분포와 랫트와 실험견에서 얻은 신장 시간방사능곡선이 Re-188-DTPA가 신장을 통해 빠르게 제거된다는 것을 밝혔다. 이러한 결과는 Re 188-DTPA를 관상동맥의 재협착을 방지하기 위해 관상동맥풍선 성형술시 풍선에 주입하는 방사성 동위원소로 사용하여도 좋음을 시사한다.

• 대한수의학회지
• /
• 제64권2호
• /
• pp.10.1-10.9
• /
• 2024

Hyperthyroidism, characterized by elevated thyroid hormone levels and thyroid gland hyperplasia or adenoma, is a prevalent endocrinopathy in older cats. Treatment options include antithyroid drugs, surgical thyroidectomy, and radioiodine therapy (RAIT), which is non-invasive treatment option that can achieve complete remission. However, efficacy and safety of RAIT in hyperthyroid cats have not been investigated in South Korea. This study includes 10 hyperthyroid cats with RAIT. Initial assessments comprised history, physical examination, blood analysis, and serum total T4 (tT4) concentration. Thyroid scintigraphy revealed hyperactivity and enlargement of thyroid gland at 24 hours before the RAIT. Radioiodine (RAI) was injected subcutaneously with 2 to 6 mCi, determined by the fixed dose or the scoring system based on severity of clinical signs, tT4 concentration, and thyroid size individually. After RAIT, the concentration of serum tT4 and liver enzymes were significantly decreased at discharge. However, no significant differences were noted in blood urea nitrogen, creatinine, symmetric dimethylarginine, hematocrits, and white blood cell counts pre- and post-treatment. Although 4 cats received RAI twice, clinical signs disappeared and tT4 levels decreased following the RAIT. All 10 cats achieved complete remission after 6 months without critical adverse effect. The safety and the effectiveness of RAIT was confirmed based on protocols reported other countries. Therefore, RAIT could be considered the treatment option and prevent adverse effects from medication or surgery. This preliminary study presents the first evaluation of RAIT for hyperthyroid cats using locally produced RAI in South Korea and provide valuable insight for clinicians and further studies.

• 대한방사선기술학회지:방사선기술과학
• /
• 제39권2호
• /
• pp.237-246
• /
• 2016

방사성동위원소 사용시설 내/외 화장실 표면 방사선량률과 공간 방사선량률을 측정하여 화장실을 이용하는 환자 이외 방사선작업종사자 및 환자보호자 등의 안전성을 확보하고 방사선 방어 연구에 대한 기초 자료로 제시 하고자 한다. 2014년 5월 1일부터 7월 31일까지 인천광역시 소재 종합병원 방사성동위원소 사용시설 내/외 화장실 4곳의 공간 방사선량률과 작업 전/후 표면 방사선량률을 각각 측정하였다. 의료기관별 방사성동위원소 사용시설 내 화장실 이용 실태조사 결과 환자뿐만 아니라 환자 보호자, 일부 방사선 작업종사자까지 다양하게 이용하고 있었다. 화장실 내 공간 방사선량률 측정 결과 핵의학적 검사 중 감마촬영실을 이용하는 화장실의 누적 공간선량률은 8.86 mSv/hr으로 가장 높게 측정되었고, 방사성옥소 치료실 화장실은 7.31 mSv/hr, PET촬영실 화장실 2.29 mSv/hr, 외래 진료과 화장실 0.26 mSv/hr으로 각각 측정되었다. 방사성동위원소 작업 전/후 화장실 내 표면 방사선량률을 측정한 결과 대부분 환자 배설물이 직접 닫는 변기 앞에서 표면 방사선량률이 가장 높게 측정되었고, 화장실 내 중앙, 입구 순으로 측정되었다. 개봉선원은 물리적 반감기가 짧고 에너지가 낮아 비교적 안전하여 방사선 관리구역에서 안전하게 사용되고 있다. 그러나 저에너지 이며 짧은 반감기의 방사선원이라 하더라도 환자에게 투여되면 그 이후 환자는 움직이는 방사선원이 되며 환자가 이용하는 장소는 배설물에 의한 방사선 오염 장소가 된다. 따라서 효과적으로 유효선량을 최소화하고 불필요한 피폭선량을 줄이기 위해 방사성동위원소 투여 후 충분한 수분 섭취를 독려하여 생물학적 반감기를 낮추고, 물리적 반감기가 허용 선량이하로 될 때까지 주변인은 환자로부터 가급적 멀리 떨어져 생활하도록 권고되어야 한다.